Site Map
 
 

 

 
 

 

Sonablate

System Information

Operations

Results

Users

Clinical Publications


THS International

Home

Distribution Information

Contact Information

   

SONABLATE® 500
 

What Are the Results?

Over 7,000 men have been treated for localized prostate cancer with the advanced Sonablate® 500 HIFU system by over 200 of the top urologists at over 100 centers worldwide.  The system has been reported by these urologists to perform as follows:

 

For localized prostate cancer therapy:

Patients with Pre-Treat PSA:
Less than 10.0ng/ml  93%
10.0 – 20.0ng/ml 75%

5- Year Success Rate:

(for all risk groups)

77%

Overall Success Rate:* 

*Sonablate® 500 with ver. 4 software and features only

94%

Presentation by T. Uchida of Tokai University Hachioji Hospital, Tokyo, Japan at American Urology Association HIFU Users Meeting 2007 with three year follow-up data of 54 patients.

 

 

For salvage therapy of localized prostate cancer:

After EBRT: 
PSA Nadir < 0.5 after 3 months: 74% success
Overall Success rate: 78%

Paper published in the British Journal of Urology, March 2008 by M. Emberton, H. Ahmed, R. Illing, et. al. University College Hospital London, London, England.

 

 

Quality of Life:

Studies show that Quality Of Life (QOL) factors did not change significantly for patients pre and post HIFU therapy*

 

FACT-G  Pre: 48.8 Post: 50.5
FACT-P Pre: 13.5 Post: 12.6
IIEF-5 Pre: 7.2 Post: 6.3

Poster presentation by T. Uchida of Tokai University Hachioji Hospital, Tokyo, Japan at Japan Endourology & ESWL Conference, Okayama, Japan, November 2004.

 

 

 

Complications:

Erectile Dysfunction  15 – 25%
Urethral Stricture 6 – 25%
Incontinence 1 – 11%
Urinary Tract Infections 0 – 10%
Retrograde Ejaculation 0 – 9%
Epididymitis 0 – 6%
Recto-urethral Fistula 0 – 3%

Best and most severe range of complications taken from T. Uchida, “Five Years Experience of Transrectal High-Intensity Focused Ultrasound Using the Sonablate Device in the Treatment of Localized Prostate Cancer”, in the “International Journal of Urology”, Vol. 13 No. 3 March 2006, and M. Emberton, “Sonablate 500 Transrectal High-Intensity Focused Ultrasound for the Treatment of Localized Prostate Cancer” in “Expert Review of Medical Devices” March 2006.

   

 

©2005-2011 THS International, Inc.